New Market Report: Pakistan Pharmaceuticals & Healthcare Report Q4 2015

Healthcare expenditure in Pakistan will grow strongly, albeit from a low base. Central to this trajectory is the rise in household incomes as out-of-pocket health spending remains a dominant source of healthcare financing. This is further supported by the higher health expenditure by administrative unit authorities which have outlined long-term medical strategies. At the sub-national level, the strongest commercial prospects for pharmaceutical and medical device companies will be in the more economically developed provinces of Punjab and Sindh.

Headline Expenditure Projections

Full Report Details at
- http://www.fastmr.com/prod/1032042_pakistan_pharmaceuticals.aspx?afid=301

Pharmaceuticals: PKR231.2bn (USD2.29bn) in 2014 to PRK252bn (USD2.45bn) 2015; +9.2%in local currency terms and +7.1% in US dollar terms.

Healthcare: PKR685bn (USD6.8bn) in 2014 to PKR758bn (USD7.36n) in 2015; +10.7% in local currency terms and +8.6% in US dollar terms.

Risk/Reward Index

Pakistan's Pharmaceutical Risk/Reward Index score for Q415 is 39.3 out of 100. This places it in the 16th out of 19 other markets in the Asia Pacific region. This low score is driven by the below average industry rewards with a low market expenditure in USD (scoring 10.0 out of 20.0), a low spending per capita in USD (scoring 1.2 out of 12) as well modest sector value growth (6.0 out of 12.0). Similarly the country's instability further drags down the country's risk score (13.0 out of 35).

Key Trends & Developments

The Pakistan Pharmaceutical Manufacturer's Association in May 2015 has announced its intention to expand its annual export of medicines. As part of a broader vision, the association seeks to establish at least 10 US Food and Drug Administration accredited medicine manufacturing units in Pakistan.

In June 2015, the Sindh High Court has directed the preservation of procurement records for hepatitis B and C treatments in FY2014-15. This comes as the tender granted to multinational drugmakers were challenged by local companies.

The Pakistan Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Pakistan Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Pakistan pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Pakistan, to test other views - a key input for successful budgeting and strategic business planning in the Pakistani pharmaceutical and healthcare market.
* Target business opportunities and risks in the Pakistani pharmaceutical and healthcare sector

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Mexico Pharmaceuticals & Healthcare Report Q4 2015
- Thailand Pharmaceuticals & Healthcare Report Q4 2015
- Central America Pharmaceuticals & Healthcare Report Q4 2015
- Croatia Pharmaceuticals & Healthcare Report Q4 2015
- Australia Pharmaceuticals & Healthcare Report Q4 2015